Universidad De Navarra

Innoup Farma, S.l.

Centro Nacional De Tecnologia Y Seguridad Alimentaria, Laboratorio Del Ebro

Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet)

Universidad Nacional De Córdoba

Digna Biotech, S.l.

Centro Nacional De Tecnologia Y Seguridad Alimentaria

Instituto Cientifico Y Tecnologico De Navarra, S.a.

Centro Nacional De Technología Y Seguridad Alimentaria (cnta)

Juan Manuel Irache Garreta

Ana Romo Hualde

Carlos Javier González Navarro

Maite Agüeros Bazo

Carolina González Ferrero

Irene Esparza Catalán

Raquel Virto Resano

Hesham H A Salman

Carlos Gamazo De La Rasilla

Francisco Borras Cuesta

Jesus Prieto Valtuena

Maria Luisa Sanz Larruga

Beatriz San Román Aberasturi

Sara Gómez Martinez

Javier Ochoa Reparaz

Krassimira Pavlova Yoncheva

Javier Dotor De Las Herrerias

Fernando Martinez Galan

Beatriz Marín Calvo

Carolina González-Ferrero

Marta Ferrer Puga

Rebeca Peñalba Sobrón

Daniel Alberto Allemandi

Carolina Boiero

Juan Manuel Llabot

Inés Luis De Redíin Subirá

Iván Peñuelas Sánchez

Gemma Quincoces Fernández

Judit Huarte Ciganda

Laura Inchaurraga Casadamón

Miguel Angel Campanero Martínez

Luisa Fernanda Ruiz Gatón

Nekane Martín Arbellá

Carlos Javier GONZÁLEZ Navarro

Irene Esparza CATALÁN

Luisa Fernanda Ruiz GATÓN

Nekane MARTÍN ArbellÁ

Laura Inchaurraga CASADAMÓN

Hesham HA Salman

Miguel Angel Campanero MARTÍNEZ

Rebeca PEÑALBA SOBRÓN

Maite Agueros Bazo

Irene Esparza Catalan

Carlos Javier Gonzalez Navarro

Carolina Gonzalez Ferrero

Miguel Angel Campanero Martinez

Nekane Martin Arbella

Laura Inchaurraga Casadamon

Luisa Fernanda Ruiz Gaton

Maite AGÜEROS Bazo

Carolina GONZÁLEZ Ferrero

Inés Luis De REDÍN SubirÁ

Gemma Quincoces FERNÁNDEZ

Iván PEÑUELAS SÁNCHEZ

Beatriz MARÍN Calvo

Sara Gomez Martinez

Beatriz San Roman Aberasturi

Hesham Ha Salman

Rebeca Penalba Sobron

The present invention refers to nanoparticles comprising a core, said core comprising a non-crosslinked albumin matrix and a monoclonal antibody, optionally coated with a non-ionic polymer for use as a medicament, to a pharmaceutical composition comprising said nanoparticles, as well as their use in the treatment of cancer an ocular diseases.

Albumin nanoparticles for the treatment of cancer and ocular diseases

The invention relates to self-assembling microparticles comprising a solid matrix and probiotic bacteria, wherein the solid matrix comprises soybean protein and a divalent or trivalent metal, and wherein the probiotic bacteria are distributed throughout the solid matrix; said matrix protects said probiotic bacteria during processing, storage, as well as during transit through the gastrointestinal tract, thus prolonging their lifetime and facilitating release into the intestine and improving their probiotic effect. The present invention also relates to the method for obtaining the self-assembling microparticles and to the products and compositions incorporating them.

Microparticles for encapsulating probiotics, obtaining said microparticles and uses thereof

The present invention relates to nanoparticles for encapsulating biologically active compounds, comprising a matrix of new polymer conjugates. The invention also relates to a process for producing both the conjugates and nanoparticles, to compositions containing said conjugates or nanoparticles, and applications thereof. The invention is applicable in the pharmaceutical sector and in the nanotechnology sector.

Nanoparticles for encapsulating compounds, the preparation and uses thereof

The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, comprising a casein matrix, a basic amino acid and a metal selected from a divalent metal, a trivalent metal and combinations thereof. Said nanoparticles can encapsulate a water soluble or fat soluble biologically active compound. The invention is applicable in the food, pharmaceutical and cosmetic sectors and in the nanotechnology sector.

Nanoparticles for the encapsulation of compounds, preparation thereof and use of same

The invention relates to microparticles comprising a matrix formed by casein and chitosan, and probiotic bacteria; said matrix protects said probiotic bacteria during (i) processing, (ii) storage and (iii) transit through the gastrointestinal tract, prolonging their lifetime. The present invention also relates to the method for obtaining the microparticles and to the products and compositions incorporating them.

Microparticles for encapsulating probiotics, production and uses thereof

The invention relates to nanoparticles comprising a biodegradable polymer, a cyclodextrin or a derivative thereof, and a biologically active molecule. Said nanoparticles can associate large amounts of biologically active molecules, especially of a hydrophobic nature, and release the biologically active molecule providing sustained and constant plasma levels thereof when they are administered orally or through any other mucosa of the organism.

Nanoparticles comprising a cyclodextrin and a biologically active molecule and uses thereof

The present invention relates to nanoparticles for the encapsulation of compounds, the obtaining and uses thereof. The nanoparticles comprise a zein matrix and a basic amino acid. The nanoparticles can encapsulate a water-soluble or fat-soluble biologically active compound. It is applicable in the food, pharmaceutical and cosmetic sectors and in the nanotechnology sector.

Nanoparticles for encapsulation of compounds, the production and uses thereof

The composition for stimulating an immune response in a subject comprises methyl vinyl ether and maleic anhydride copolymer-based nanoparticles. Said nanoparticles may further contain an allergen or an antigen and/or an immunostimulating agent, which may be contained inside said nanoparticles and/or at least partially coating the surface of said nanoparticles, and optionally a cross-linking agent. The immune response stimulating composition is useful as an adjuvant in immunotherapy and vaccines.

Immune response stimulating composition comprising nanoparticles based on a methyl vinyl ether-maleic acid copolymer

The present invention relates to nanoparticles comprising a biodegradable polymer, preferably the vinyl methyl ether and maleic anhydride (PVM/MA) copolymer, and a polyethylene glycol or derivatives thereof. These nanoparticles are easy to produce and provide excellent bioadhesion, size and zeta potential characteristics making them suitable for the administration of active molecules. The selection of the type of polyethylene glycol used in their production allows suitably modulating the characteristics of these nanoparticles, which can be advantageously used according to the type of drug to be carried and/or the method of administration of the pharmaceutical formulation. pegylation is carried out by simple incubation for a short time period of the two macromolecules in question, without needing to have to resort to the use of organic solvents with high toxicity or long and laborious organic synthesis processes. Furthermore, the pegylation process can be associated to the process of encapsulating the biologically active molecule.

Pegylated nanoparticles

A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-&#x3b2;, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-&#x3b2;, for the treatment of skin fibrosis by topical application. The method is shown effective in an animal model of bleomycin-induced skin sclerosis, to a reduction both of the skin fibrosis and of the content of soluble collagen, without any signs of systemic toxicity being detected. This shows that P144 is effective for topical application in mammals for treating fibrotic skin diseases and pathological scarring of the skin. For the administration of this peptide, stable compositions are also supplied, with pleasant appearance without being greasy, with good spreading characteristics and with a viscosity that permits it to be processed easily in industrial plant, and which are suitable for administering the peptide to humans.

Method for the treatment of skin fibrosis and suitable compositions for such treatment

Growing community of inventors

Pamplona-Navarra, Spain

Juan Manuel Irache Garreta